From Gut Dysbiosis to Skin Inflammation in Atopic Dermatitis: Probiotics and the Gut–Skin Axis—Clinical Outcomes and Microbiome Implications
Authors:
- Adina Elena MicuAMAdina Elena Micu
- Ioana Adriana PopescuIPIoana Adriana Popescu
- Ioana Alina HalipIHIoana Alina Halip
- Mădălina MocanuMMMădălina Mocanu
- Dan VâțăDVDan Vâță
- Andreea Luana HulubencuAHAndreea Luana Hulubencu
- Dragoș Florin Gheucă-SolovăstruDGDragoș Florin Gheucă-Solovăstru
- Laura Gheucă-SolovăstruLGLaura Gheucă-Solovăstru
Open Access
- 29 December 2025
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (1) , 365
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease in which barrier impairment, immune dysregulation, and gut–skin dysbiosis intersect, prompting growing interest in probiotics as microbiota-modulating adjuncts. We conducted a narrative review of peer-reviewed articles indexed in PubMed, Scopus, and Google Scholar, restricted to publications from 1 January 2018 to 31 October 2025 (searches last run in December 2025). Eligible evidence included randomized controlled trials (RCTs), observational studies, and mechanistic or conceptual reviews addressing microbiome alterations and microbiota-modulating interventions in AD. Most pediatric RCTs using multistrain, Lactobacillus-dominant formulations (often combined with Bifidobacterium) reported modest improvements in AD severity and pruritus and in selected barrier- and inflammation-related biomarkers. However, direct cutaneous microbiome “restoration” outcomes were reported in a minority of studies, and most clinical evidence relies on clinical endpoints and gut–skin axis plausibility rather than longitudinal skin microbiome readouts. Single-strain regimens showed inconsistent effects, and evidence in adolescents and adults remained heterogeneous. Mechanistically, probiotics may enhance short-chain fatty acid (SCFA) signaling, dampen toll-like receptor 2/4 (TLR2/4)-nuclear factor kappa B (NF-κB) activation, and promote interleukin-10 (IL-10)- and transforming growth factor-β (TGF-β)-driven tolerance. Probiotics are a biologically plausible adjunct targeting the gut–skin axis in AD and are generally well tolerated; however, heterogeneity across trials, limited follow-up, inconsistent adverse-event reporting, and scarce skin microbiome endpoints preclude firm clinical recommendations.Keywords
This publication has 59 references indexed in Scilit:
- Association of Adult Atopic Dermatitis with Impaired Oral Health and Oral Dysbiosis: A Case-Control StudyInternational Dental Journal, 2024
- Role of stress in skin diseases: A neuroendocrine-immune interaction viewBrain, Behavior, and Immunity, 2023
- Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE– and Institute of Medicine–based recommendationsAnnals of Allergy, Asthma & Immunology, 2023
- Vaginal delivery provides skin colonization resistance from environmental microbes in the NICUClinical and Translational Medicine, 2023
- Targeting dysbiosis in psoriasis, atopic dermatitis, and hidradenitis suppurativa: the gut-skin axis and microbiome-directed therapyClinics in Dermatology, 2023
- Human skin bacterial microbiota homeostasis: A delicate balance between health and diseasemLife, 2023
- Competition between skin antimicrobial peptides and commensal bacteria in type 2 inflammation enables survival of S. aureusCell Reports, 2023
- Guidelines of care for the management of atopic dermatitis in adults with topical therapiesJournal of the American Academy of Dermatology, 2023
- Oral Administration of Live and Dead Cells of Lactobacillus sakei proBio65 Alleviated Atopic Dermatitis in Children and Adolescents: a Randomized, Double-Blind, and Placebo-Controlled StudyProbiotics and Antimicrobial Proteins, 2020
- Effect of Oral Administration of a Mixture of Probiotic Strains on SCORAD Index and Use of Topical Steroids in Young Patients With Moderate Atopic DermatitisJAMA Dermatology, 2018